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Abstract
Human immunodeficiency virus type 1 (HIV-1) resistance to protease inhibitors (PI) results from mutations in the viral protease
(PR) that reduce PI binding but also decrease viral replicative capacity (RC). Additional mutations compensating for the RC loss
subsequently accumulate within PR and in Gag substrate cleavage sites. We examined the respective contribution of
mutations in PR and Gag to PI resistance and RC and their interdependence using a panel of HIV-1 molecular clones carrying
different sequences from six patients who had failed multiple lines of treatment. Mutations in Gag strongly and directly
contributedtoPIresistancebesidescompensatingforfitnessloss.ThiseffectwasessentiallycarriedbytheC-terminalregionof
Gag (containing NC-SP2-p6) with little or no contribution from MA, CA, and SP1. The effect of Gag on resistance depended on
the presence of cleavage site mutations A431V or I437V in NC-SP2-p6 and correlated with processing of the NC/SP2 cleavage
site. By contrast, reverting the A431V or I437V mutation in these highly evolved sequences had little effect on RC. Mutations in
the NC-SP2-p6 region of Gag can be dually selected as compensatory and as direct PI resistance mutations, with cleavage at
the NC-SP2 site behaving as a rate-limiting step in PI resistance. Further compensatory mutations render viral RC independent
of the A431V or I437V mutations while their effect on resistance persists.
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Introduction
The Human Immunodeficiency virus type 1 (HIV-1) protease
(PR) is a key enzyme in viral replication and a major target for
therapeutic intervention. Protease inhibitors (PI) are the backbone
of some of the most active combinations of antiretroviral drugs
used in the treatment of HIV-infected patients. The long-term
efficacy of these compounds, however, is threatened by the
emergence of viral resistance and subsequent spread of resistant
virus. HIV-1 resistance to PIs is promoted by gradual accumu-
lation of amino-acid substitutions in PR, resulting in altered PI
binding [1–5]. Resistance-promoting changes in PR generally also
decrease viral replicative capacity (RC) due to decreased
processing of the natural substrate. Accordingly, additional
mutations accumulate in PR over time that mainly compensate
for these losses in RC, but may also contribute to resistance
directly [1–3,6]. The biological effect of PI resistance mutations
thus has to be viewed as the product of their effect on enzyme
inhibition (resistance) and on enzyme activity (RC).
Besides mutations directly affecting PR, several mutations in the
Gag polyprotein, the main substrate of PR, have been found to
play a significant role in the evolution of PI resistance [7–13].
These mutations were generally classified as compensatory
mutations that restore activity of the mutated PR for its natural
substrate [7–9,12,14,15]. Particular attention has been turned to
mutations in the region surrounding the NC-SP2-P6 cleavage sites
at the C-terminus of Gag. Figure 1 gives an overdrive of these
mutations and of their position in the NC-SP2-p6 region of HIV-1
Gag. The most frequently observed cleavage site mutations in this
region are substitution A431V, located at position P2 of the NC-
SP2 cleavage site, mutation L449F at position P1’ of the SP2-P6
cleavage site, and mutations K436R and I437V, situated
immediately downstream of the NC-SP2 site. Interestingly, some
of these mutations appear to depend upon the presence of specific
mutations in PR: Mutation A431V is mostly observed in PI-
resistant viruses carrying mutations V82A and/or M46I in PR
[16]. Mutation L449F is frequently seen in viruses with mutation
I84V in PR [16]. Neither of these two substitutions are seen in
wild-type, protease inhibitor-naı ¨ve viruses. Substitution P453L is a
polymorphism found in some inhibitor-naı ¨ve viruses. It is,
however, seen with significantly higher frequency in resistant
viruses carrying the I84V mutation in PR [16] and also specifically
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association with L449F [12].
In this context, two main questions remain to be answered.
First, although some studies have identified Gag polymorphisms
outside of cleavage sites that appeared to be important for the
replicative capacity of viruses with PR mutations [15–20], the
extent to which changes in the matrix (MA), capsid (CA),
nucleocapsid (NC) proteins and in adjoining cleavage sites
participate in evolution of viruses under PI pressure in vivo has
not been fully evaluated. Second, the potential impact of Gag
cleavage site mutations on viral resistance, in addition to their well
established compensatory effect on viruses carrying PI resistance
mutations, remains to be established. Nijhuis et al. [13] recently
reported the emergence of viruses carrying mutations K436E and
I437V (Figure 1) within the SP2 linker peptide of Gag following in
vitro selection for HIV-1 resistance to an experimental PI. These
mutations in Gag preceded the detection of mutations in PR, and
decreased HIV susceptibility to several PIs. It is currently not
clear, however, whether mutations in Gag have a selective impact
on the level of resistance under PI pressure in vivo, and whether this
impact could be independent of the effect of these mutations on
viral RC.
In this study, we have constructed recombinant viruses carrying
different Gag-Pol segments from the plasma of HIV-1 infected
subjects in whom viral resistance had evolved to high levels
following prolonged antiretroviral treatment failure. Recombinant
viruses were tested phenotypically for resistance and replicative
capacity. In most cases, the loss of RC resulting from resistance
mutations in PR was partially compensated by the NC-SP2-P6
region of Gag while addition of the MA and CA domains had no
effect. The presence of patient-derived NC-SP2-P6 resulted in
strong increases in the IC50 of most PIs, establishing the important
role of this region in determining resistance. Selective reversion of
mutations A431V or I437V in a subset of these recombinant
viruses produced a strong reduction in resistance, but only a minor
effect on replication capacity. The effects on viral resistance
correlated with processing at the NC-SP2 cleavage site, revealing
the importance of this cleavage event for HIV-1 resistance to PIs.
Our results suggest a second pathway of resistance in patients
failing a PI-containing regimen, establish a direct effect of Gag
cleavage site mutations on antiviral resistance beyond their
previously described compensatory role, and identify NC-SP2
cleavage as a limiting step in resistance development in vivo.
Results
Construction of recombinants carrying patient-derived
Gag-Pol sequences
Gag-Pol HIV-1 sequences from 6 patients were studied. The PR
and RT sequences of these viruses contained multiple resistance
mutations, as defined according to the IAS-USA table, and are
shown on Figure 2A (PR) and Figure 2B (RT). The mean number
of mutations in PR was 8.8 (range: 6–11). All 6 viruses also carried
mutations in the NC-SP2-P6 cleavage region of Gag (Figure 2C).
Mutation A431V, at the P2’ position of the NC-SP2 cleavage site
was found in 4 viruses. Mutation I437V, immediately downstream
of that cleavage site, was found in 2 viruses, and mutation L449H,
at the P1 position of the SP2-p6 cleavage site was found in one
virus, in association with the A431V mutation. Interestingly,
mutations A431V and I437V were found to be mutually exclusive
in these 6 viruses, which was also the case in the 20 other patients
of the ANRS 109 study (data not shown).
For each of these 6 viruses, 4 different Gag-Pol recombinant
clones were constructed (Figure 3). Clones BS contained the whole
of Gag, PR and RT from patient virus, down to the junction
between RT and RNAse H. Clones AS carried patient-derived C-
terminal half of NC, SP2 spacer peptide and p6, in association
with PR and RT from the same patient. Clones XS had only PR
Figure 1. Principal mutations in the NC-SP2-P6 region of HIV-1 Gag selected in viruses exposed to protease inhibitors in vivo or in
vitro. The upper part of the figure lists cleavage site mutations most often observed in viruses exposed to protease inhibitors in vivo. The cleavage
site mutations shown in the lower part of the figure were selected by in vitro passage of laboratory strains of HIV-1 in the presence of protease
inhibitors as described in Doyon et al. [7] and in Nijhuis et al. [13].
doi:10.1371/journal.ppat.1000345.g001
Author Summary
Protease inhibitors are among the most active antiviral
drugs used in the treatment of Human immunodeficiency
virus type 1 (HIV-1) infection. The efficacy of these
compounds, however, can be threatened by the emer-
gence of viral resistance, the result of the gradual
accumulation of specific mutations in the viral protease.
HIV-1 resistance to protease inhibitors often results in
impaired protease function and in the loss of the
replicative capacity of the virus, an effect that can be
partially corrected by selection of compensatory mutations
in one of the natural substrates of the protease, the Gag
protein. In this study, we have found that Gag mutations
not only correct viral replicative capacity but also play a
major and direct role in resistance. We observed that this
effect is essentially mediated by mutations in the C-
terminal region of Gag, and that it correlates with the
extent of cleavage downstream of the Gag nucleocapsid
protein. Our results establish that mutations in Gag
constitute a second and important pathway of HIV-1
resistance to protease inhibitors in patients failing
antiretroviral treatment.
HIV-1 Gag Mutations and Resistance
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Gag. Finally, clones BX carried the whole Gag from patient
viruses, in association with NL4-3 PR and RT. It is noteworthy
that in the latter, the transframe region of the Gag-Pol polyprotein
was patient-derived, while the last 12 amino acids at the C-
terminus of the Gag polyprotein were from NL4-3. For each virus,
the AS, XS and BX clones were derived from a single BS clone.
Effect of different segments of Gag on PI resistance
All 4 clones from each of the 6 patients were tested
phenotypically for resistance to PIs. The results of these analyses,
representing mean6SD of at least 3 independent experiments, are
shown on Table 1, where resistance is expressed as a fold-change
in IC50 relative to NL4-3. Six distinct PIs were tested: indinavir
(IDV), nelfinavir (NFV), amprenavir (APV), saquinavir (SQV),
lopinavir (LPV) and atazanavir (ATV). Viruses carrying patient-
derived PR, RT and complete Gag sequences (BS clones) were
strongly resistant to most PIs tested, in accordance with clinical
failure of the respective patients. In contrast, resistance was found
markedly lower in viruses carrying only patient-derived PR and
RT in absence of any patient-derived Gag sequences (XS clones).
This finding emphasizes the critical importance of HIV-1 Gag in
viral resistance to PIs. When a shorter segment of Gag
encompassing the NC-SP2-P6 region was added to the same
highly mutated PR and RT sequences (AS clones), resistance levels
were comparable to those measured with clones carrying the full
Gag coding sequence (BS clones), strongly suggesting that most of
the resistance impact of Gag is restricted to the NC-SP2-p6 region.
Therefore, the MA and CA proteins, together with their flanking
cleavage sites, do not appear to play a significant role in PI
resistance selection in vivo, at least for this group of heavily pre-
treated patients. Interestingly, all BX clones, which carried
patient-derived Gag but wild-type PR and RT, exhibited
increased IC50 levels relative to NL4.3, an effect that ranged
from 1.6-fold to 5.6-fold, suggesting that even in the presence of
wild-type PR, changes in Gag occurring during the course of HIV
evolution under selective pressure by PIs in vivo exert a clear effect
on HIV-1 suseptibility to these compounds.
Effect of different regions of Gag on replicative capacity
As expected, the presence of patient-derived Gag sequences had
a strong positive impact on the RC of the multiply resistant viral
clones. The RC of XS clones, which lacked patient-derived Gag,
was markedly lower than that of BS clones, carrying the whole
Gag sequence from patient plasma: the mean RC of XS clones
was 5.6% of NL4-3, and the mean change in RC for XS clones
relative to cognate BS clones was a 19.5-fold decrease. The
greatest such effect was seen with the VIS13 virus (53.6-fold
decrease) and the lowest with VIS16 (2.2-fold decrease). Similar to
what was seen for resistance, the RC of most BS clones did not
differ from that of cognate AS clones, again emphasizing the
absence of a significant impact of MA and CA on resistance-
associated loss of RC. It is noteworthy that substantial variation in
RC was seen among the BS clones from different patients, with the
lowest (VIS16) at 31.966.0% and the highest (VIS13) at
117.9630.3%. Similarly, marked variation in RC was observed
Figure 2. Genotypes of the viruses used in the study. (A) Protease resistance genotypes, showing mutations at positions identified as critical
for resistance to protease inhibitors according to the IAS-USA resistance mutations table, as shown at http://www.iasusa.org/resistance_mutations/
mutations_figures.pdf. (B) Reverse transcriptase resistance genotypes. (C). Aminoacid polymorphisms in the NC-SP2-p6 region of Gag, relative to the
sequence of NL4-3.
doi:10.1371/journal.ppat.1000345.g002
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absence of mutated PR and RT. For 4 of the clones, the RC of BX
clones was higher than that of the cognate BS clone, suggesting
that resistance mutations in PR and/or RT continued to exert
some deleterious effect on RC in spite of compensatory mutations
in Gag. For 2 viruses, however, the RC of the BX clone was lower
than that of the BS clone (VIS13, VIS18). In these cases, the RC of
the BX clone was also lower than that of the AS clone, whereas the
RC of BS and AS clones were similar. Taken together, these
findings are consistent with the possibility that these viruses carried
mutations in the NC-SP2-p6 region able to facilitate replication of
viruses with resistance mutations in PR and RT, but whose
presence is deleterious for replication of viruses carrying wild-type
PR and RT sequences.
Overall, the increase in RC resulting from the presence of
patient-derived Gag sequences in clones carrying highly mutated
PR and RT sequences was almost strictly parallel to the increase in
resistance observed with the same clones. In general, however, the
effect measured on RC was stronger than the resistance effect.
Thus, for example, the mean change in IDV resistance for XS
clones relative to BS clones was a 5.2-fold decrease, compared to
the 19.5-fold loss in RC.
Individual role of NC-SP2 cleavage site mutations A431V
and I437V in the ability of patient-derived Gag sequences
to enhance RC and resistance
Having established that the determinants in Gag able to exert
an enhancing effect on HIV-1 RC and resistance to PIs are
essentially restricted to the NC-SP2-p6 region, we sought to
evaluate the precise role of NC-SP2 mutations A431V and I437V
in this phenomenon. We therefore selected XS clones from 3
patients and introduced the A431V (seen in VIS13 and VIS18
viruses) or the I437V (seen in VIS16) mutations into the NL4-3-
derived Gag sequences, yielding the VIS13XS431V, the
VIS16XS437V and the VIS18XS431V mutants (Figure 4). In
parallel, these NC-SP2 cleavage site mutations were reverted back
to wild-type in the patient-derived Gag sequences of the
corresponding BS clones, yielding the VIS13BS431A,
VIS16BS437I and VIS18BS431A mutants.
As seen in Figure 5, the reversion of mutations A431V or I437V
in BS clones from patients VIS13 and VIS16 resulted in a strong
decrease in the IC50 of the three PIs tested, corresponding to a loss
of resistance. In these two viral backgrounds, the decrease in IC50
resulting from reversion of the NC-SP2 cleavage site mutations was
equivalent to that seen when replacing the whole Gag region from
patient virus with that of NL4-3 (i.e., in the XS clones). Coherent
with this observation, when mutations A431V and I437V were
introduced in the XS clones, a strong increase in IC50 was seen,
back to levels close to those seen with the BS clones. This
observation strongly suggests that in highly resistant viruses, the
resistance impact of the NC-SP2-p6 region is essentially carried by
NC-SP2 cleavage site mutations. A slightly different and less clear
picture was seen with virus VIS18, where the IC50 effect of
reversion of A431V was relatively modest, in particular with IDV,
and where this effect did not seem to be quite as pronounced as that
seen with the XS clone. Nonetheless, introduction of A431V in
VIS18XS produced a strongand significant increase inIC50 to all 3
tested drugs, to levels comparable to those seen with VIS18BS.
We next examined the effect of these mutations on RC
(Figure 6). Reversion of NC-SP2 cleavage site mutations resulted
in a moderate or no reduction in RC, contrasting with the much
Figure 3. Construction of recombinant clones carrying HIV-1 Gag-Pol sequences from treated patients. Schematic representation of the
different segments of Gag-Pol used to create the clones used in the study, as described in Materials and Methods. Black rectangles represent
sequences from patient virus; grey rectangles represent sequences from pNL4-3. The restriction enzymes and restriction sites used for the
constructions are indicated. MA, matrix protein; CA, capsid protein; NC, nucleocapsid protein; SP2, spacer peptide 2; PR, protease; RT, reverse
transcriptase.
doi:10.1371/journal.ppat.1000345.g003
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Furthermore, the effect on RC was far less pronounced than that
of the total removal of patient-derived Gag sequences, as seen in
XS clones. In VIS13, reversion of A431V from VIS13BS reduced
RC by about half, a reduction that was strikingly lower than that
seen with VIS13XS. In VIS18, the reversion of A431V from
VIS18BS did not significantly change RC, contrasting with the
strong reduction in RC seen in VIS18XS. In VIS16, the change in
RC produced by reversion of I437V was again marginal, but in
this virus, only a small change in RC was seen when comparing
the BS and the XS clone. These results show that NC-SP2
mutations are not sufficient to explain the losses of RC that
characterize clones with highly mutated PR and RT sequences
and in which patient-derived Gag sequences are absent. They
suggest that sequence determinants in NC-SP2-P6 outside of the
NC-SP2 cleavage site account in part for this phenomenon,
confirming the published results of Myint et al. [19]. Remarkably,
however, when NC-SP2 cleavage site mutations were introduced
in the XS clones, in which all Gag sequences are derived from
NL4-3, we observed almost complete restoration of RC back to
levels measured in BS clones. This surprising result shows that in
viruses having evolved under prolonged selective pressure by PIs,
RC is dependent upon complex interactions between NC-SP2
cleavage site mutations and their environing sequences, while
single Gag mutations have a much stronger effect on RC when
introduced into an otherwise wild-type background.
Effect of NC-SP2 cleavage site mutation on Gag
processing during viral maturation
Kinetic analyses of HIV-1 Gag cleavage by wild-type PR have
revealed that NC-SP2 is one of two sites, together with CA-SP1,
where cleavage occurs with slowest kinetics. The importance of
NC-SP2 cleavage in infectivity is unclear and has been recently
challenged by results showing that mutations obliterating cleavage
at this site had little effect on HIV-1 infectivity [21]. Given the
remarkable effect of NC-SP2 cleavage site mutations on the RC
and on the levels of resistance expressed by viruses with highly
resistant PR, we examined extent that these phenotypic changes
were reflected by differences in PR cleavage at this particular site.
Virions from clones VIS13BS, VIS13BS431A, VIS13XS, and
VIS13XS431V were produced by HeLa cells in the absence or in
the presence of lopinavir at two concentrations. The protein
content of purified virions was analyzed by quantitative western
blotting using antibodies against CA and NC.
Figure 7 shows representative results from one out of three
independent experiments. Analysis of the CA-reactive products
Table 1. Resistance to protease inhibitors and replicative capacity of Gag-recombinant proviral clones.
IDV* NFV* APV* SQV* LPV* ATV* RC**
VIS09 BS 4362.2 31.965.4 2.860.4 38.868.2 98.2627.1 80.0636.1 54.465.2
AS 57.3615.2 40.5610.0 3.560.5 57.5611.3 85.6622.5 95.5646.3 29.369.1
XS 17.566.5 16.066.0 1.260.4 24.1612.6 42.9622.8 26.869.6 3.761.7
BX 3.761.3 2.761.3 2.560.2 2.560.5 5.363.1 4.661.2 219.6637.2
VIS13 BS 173.5639.6 127.4647.2 52.9626.8 20.864.7 .221 49.4613.7 117.9630.3
AS .237 173.7654.7 76.4624.6 28.963.9 .221 72.7617.1 131.6625.4
XS 40.3612.6 43.2616.5 12.564.5 8.866.9 98626.7 8.363.4 2.261.1
BX 2.360.7 2.261.1 1.660.1 2.460.2 3.760.3 2.660.7 62.2612.3
VIS15 BS 33.766.1 13.565.8 15.462.1 1.760.3 33.4615.1 23.063.1 61.9615.1
AS 20.964.2 10.263.3 11.062.5 1.260.2 24.669.6 16.263.6 50.4611.2
XS 2.560.7 1.460.9 1.660.6 0.260.1 3.661.2 2.260.8 3.461.2
BX 3.860.4 3.260.7 2.960.1 2.161.0 5.661.8 4.962.3 87.8621.6
VIS16 BS 35.2619.6 19.8610.3 1.360.4 59.266.1 33.368.6 34.867.9 31.966.0
AS 46.3612.2 21.467.7 1.560.4 .66 56.2622.1 51.165.5 22.568.5
XS 9.963.5 6.662.9 0.560.03 21.462.7 16.966.4 15.660.9 14.364.1
BX 3.060.5 2.661.0 1.960.2 2.760.5 3.761.2 3.261.6 232.4639.4
VIS18 BS 23.266.3 19.366.9 20.962.0 6.561.3 31.2613.6 73.5613.1 45.369.1
AS 3068.4 28.2615.4 24.161.7 8.362.4 32.8611.6 65.2622.5 53.5612.3
XS 5.461.4 6.963.7 5.961.0 1.660.4 7.661.6 17.160.9 3.861.6
BX 3.060.4 2.060.5 1.860.9 1.460.5 2.360.4 1.860.4 3664.3
VIS20 BS 97.1629.6 55.9631.3 3.860.7 16.763.8 153.3664.3 78.3629.3 103.968.5
AS 114.1615.4 65.4617.1 5.361.3 24.563.2 187.3655.2 184.1650.0 45.7618.9
XS 28.7612.8 8.660.8 0.960.2 5.661.2 40.168.8 25.662.8 6.161.9
BX 2.560.6 2.961.0 2.260.4 2.360.4 3.861.0 3.561.2 162.6648.5
Numbers are the mean of at least three independent experiments6SD.
Bold numbers indicate that the difference between AS or XS values and BS values was found statistically significant using a one-way ANOVA followed by Bonferroni’s
multiple comparison post-test.
*Resistance is expressed as a fold-change in IC50 relative to pNL4-3, as described in Materials and Methods.
**Replicative capacity (RC) is expressed as a % of pNL4-3 RC, as described in Materials and Methods.
IDV, indinavir; NFV, nelfinavir; APV, amprenavir; SQV, saquinavir; LPV, lopinavir; ATV, atazanavir.
doi:10.1371/journal.ppat.1000345.t001
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processing at 50 nM LPV, while processing of VIS13BS derived
virus was much less inhibited even at a concentration of 2,5 mM.
No significant difference in CA processing was observed when
VIS13XS or the derivatives with alterations in position 431 were
compared (Figure 7A). In contrast, processing of the NC-SP2
cleavage site was strongly dependent on the amino acid in position
431 (Figure 7B). This was reflected by the relative amounts of fully
processed NC and the intermediate cleavage product NC-SP2,
while only very small amounts of the NC-SP2-p6 product were
detectable in all cases. For virus VIS13BS, which carried all
patient-derived Gag sequences including mutation A431V, fully
processed NC amounted to ,80% of all NC-reactive products in
the presence of 0,5 mM LPV (Figure 7C). Furthermore, mature
NC was still present at .60% of all NC-reactive species in the
presence of 2,5 mM LPV, a concentration amounting to
approximately twice the IC50 of VIS13BS. Reversion of A431V
in VIS13BS (clone VISBS431A) produced a clear change in this
pattern with NC-SP2 amounting to ,65% of all NC-reactive
species at 2,5 mM LPV (Figure 7C). A very similar pattern was
seen with VIS13XS, in which all Gag sequences were derived
from NL4-3. In this case, NC-SP2 amounted to .80% of all NC-
reactive species at 2,5 mM LPV and 60% at 0,5 mM LPV.
Introducing the A431V mutation into this background reverted
the NC/NC-SP2 ratio yielding a NC processing profile compa-
rable to that of VIS13BS at all LPV concentrations.
Discussion
In this study, we addressed the contribution of Gag to the
selection of HIV-1 resistance to PIs in vivo. Our results reveal that
mutations in the NC-SP2-p6 region of Gag directly contribute to
PI resistance in addition to their compensatory role, an effect that
correlates with the extent of proteolytic processing of the NC-SP2
cleavage site. In contrast, in these samples from patients having
failed multiple lines of antiretroviral therapy, the upstream MA-
CA-SP1 region of Gag does not appear to influence PI resistance.
These results suggest a new paradigm of resistance evolution in vivo
that is further supported by recent results from in vitro selection
experiments [13].
First, we investigated the extent that cleavage site mutations in
Gag can promote resistance per se, together with their ability to
partly compensateforlossesofRCthat resultfrom mutations in PR.
Coevolution of HIV PR and its substrates in PI resistance has been
well established for specific mutations in the NC-SP2-P6 region of
Gag [7–9,12,16,22]. Most studies have emphasized the important
role of these mutations in partial compensation of the loss of HIV-1
RC that often results from PR resistance [8,9,12,14,15]. The
mechanism of this compensation has been documented for
mutation A431V, which emerges mostly in viruses carrying
resistance mutation V82A in PR. Interestingly, this Gag mutation
does not act through direct steric compensation of the structural
change in the substrate-binding domain of PR, but creates an
additional point of contact between the substrate and the substrate-
binding cavity of the enzyme. This contact is independent of the
presence of resistance mutations, thereby producing a non-specific
increase in enzymatic activity at the mutated site [23].
Comparison of recombinant viruses carrying whole patient-
derived Gag sequences together with their cognate PR and RT
sequences (BS viruses) with recombinant viruses carrying patient-
derived PR and RT only (XS viruses) revealed a remarkable
contribution of Gag cleavage site mutations A431V and I437V in
the NC-SP2-p6 region to the emergence of PI resistance in vivo
(Table 1). When the cleavage site mutations were removed by site-
directed mutagenesis in clones carrying whole patient-derived
Gag-PR-RT sequences, 2 to 5-fold reductions in resistance were
observed, at least for certain drugs. Furthermore, inserting these
mutations into viruses carrying patient-derived PR-RT sequences,
but NL4-3-derived Gag sequences usually resulted in viruses
whose resistance was equivalent to, or even higher, than that
observed for viruses carrying only patient-derived Gag-Pol
sequences. The observation that cleavage site mutations A431V
and I437V were actually acting as resistance mutations in these
highly evolved, highly resistant clinical viruses, is complementary
to a recent study [13], which reported in vitro selection for
resistance to an experimental PI using a laboratory strain of HIV-1
leading to emergence of mutations in SP2 at position 436 and 437
before any changes in PR.
Figure 4. Modification of cleavage site sequences by site-
directed mutagenesis. Schematic representation of the mutations
reverted or introduced in Gag cleavage sites by site directed-
mutagenesis, as described in Materials and Methods. Black rectangles
represent sequences from patient virus; grey rectangles represent
sequences from pNL4-3. Black arrows indicate introduction of a
cleavage site Gag mutation as found in patient-derived resistant virus
into NL4-3-derived sequences. Grey arrows indicate reversion of a
cleavage site Gag mutation from patient-derived Gag sequences back
to wild-type NL4-3 codon.
doi:10.1371/journal.ppat.1000345.g004
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I437V on viral RC was more nuanced. When cleavage site
mutations were removed by site-directed mutagenesis in clones
carrying patient-derived Gag-PR-RT sequences, RC was impaired
in some cases, but not to the extent that resistance was impaired.
Furthermore, a considerably greater loss of RC was observed
when the entire patient-derived Gag was replaced by Gag
sequences from the reference NL4-3 virus. Thus, although the
introduction of cleavage site mutations into viruses carrying NL4-3
Gag sequences and patient-derived PR-RT sequences fully
restored viral RC in all cases, the reversion of the same cleavage
site mutations from a patient-derived Gag sequence had, at most,
only a small impact on RC. Taken together, these findings suggest
that other, as yet undefined, mutations had occurred in gag in
these patient-derived viruses that partially (VIS 13, VIS16), or
completely (VIS18) compensated for the loss of fitness resulting
from protease resistance mutations, at least in the absence of PI
treatment. These findings are consistent with those of Myint et al.
[19], who showed that changes in the p6 region of Gag could
participate in partial correction of resistance-associated loss of RC.
Furthermore, the context-dependent effects of NC-SP2 cleavage
site mutations on RC indicate that these changes can be dually
selected: (i) as compensatory mutations restoring RC of PR
mutated viruses without further changes in gag and (ii) as direct PI
resistance mutations. Upon prolonged treatment, further muta-
tions in Gag outside the cleavage site may render viral RC
independent of the A431V or I437V mutations while the effect of
these mutations on resistance and thus their selective power in vivo
persists. The nature of the Gag mutations outside of cleavage site
that appear to contribute to viral RC was not investigated in this
study. As seen on Figure 2C, numerous polymorphisms, including
insertions and duplications in the p6 region of Gag, differed
Figure 5. Resistance phenotype of viral clones carrying mutations or reversions in Gag cleavage sites. Each panel shows the IC50 of the
indicated protease inhibitor for a set of clones whose construction was based on the same patient-derived HIV-1 sequences. Three sets of clones,
from three different patient-derived sequences (VIS13, VIS16, and VIS18) were tested for resistance to indinavir (IDV), amprenavir (APV), and lopinavir
(LPV). Black bars, BS clones carrying patient-derived Gag, PR, and RT; light grey bars, clones in which mutation A431V (for VIS13 and VIS 18) or I437V
(for VIS16) was reverted back to wild-type in patient-derived Gag in BS clones by site-directed mutagenesis; dark grey bars, XS clones carrying NL4-3
Gag in the presence of patient-derived PR and RT; white bars, clones in which mutation A431V (for VIS13 and VIS 18) or I437V (for VIS16) were
inserted in NL4-3-derived Gag in XS clones by site-directed mutagenesis. Single asterisks indicate that the IC50 difference between the indicated
clone and the corresponding BS clone is statistically significant. Double asterisks indicate that the IC50 difference between the indicated clone and
the corresponding XS clone is statistically significant.
doi:10.1371/journal.ppat.1000345.g005
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frequently observed in HIV-1 sequence databases. Of note, our
clones did not carry the polymorphisms described by Myint et al.
as being able to exert a compensatory effect on HIV-1 RC. We
therefore hypothesize that the RC effect seen in some of our clones
following reversion of cleavage site mutations is likely mediated by
complex combinations of non-unique natural polymorphisms,
which may vary from one virus to another according to their
overall Gag genetic context.
The mechanism through which mutations in PR substrates can
promote resistance by themselves, independently of their effect on
RC, either in the presence or in the absence of resistance
mutations in PR has yet to be explained. As discussed earlier, viral
resistance to PIs involves a balance between two competing PR
ligands: the inhibitor and the Gag or Gag-Pol polyproteins. In vitro,
the affinity constant of PIs for their target is most often in the sub-
nM range, while the affinity constant of Gag or Pol cleavage sites
for PR, which varies according to the cleavage site, has been
evaluated as being in the mM range [24]. How an increase in the
affinity constants of the latter ligand can displace binding of the
former is unclear. One explanation, however, may relate to the
different stoichiometry of PR relative to its natural substrates at the
site of HIV virion maturation [25], compared to that of PR
relative to free, active, unbound PIs at these sites. Clearly, further
work, involving precise evaluation of intracellular concentrations
of PIs at the site of viral assembly, would be needed in order to
better understand these phenomena.
The other main observation of our study is that changes in Gag
that promote increases in resistance and in RC in highly evolved,
highly resistant, viruses are essentially restricted to the NC-SP2-p6
region of Gag. In our panel of viruses, little effect of MA-CA-SP1
regions was measured either in resistance or in RC. The notable
interstrain variability in some domains of HIV-1 MA and CA, and
in particular the strong variability in the CA-SP1 cleavage site, do
not appear to play a significant role in resistance. Two viruses
constituted possible exceptions. In virus VIS09, the RC of the AS
clone, carrying only patient-derived NC-SP2-p6 in combination
with cognate PR and RT patient sequences, was significantly
different from that of the BS clone, which carried whole Gag
sequences from patient plasma. The resistance levels of the VIS09
AS clone, however, were not significantly different from those
measured with the BS clone. In virus VIS20, the same
phenomenon was observed, albeit on a smaller scale, and the
difference in RC between AS and BS clones did not reach
statistical significance. These observations further support the idea
that mutations other than NC-SP2-p6 cleavage site mutations can
help compensate for losses of viral RC associated with PI
resistance, and further suggest that mutations occurring outside
of the NC-SP2-p6 region can participate in this process. These
mutations do not, however, appear to have appreciable impact on
drug resistance.
The absence of effect of MA-CA-SP1 sequences on drug
resistance, and their only modest impact on viral fitness, strongly
suggests that cleavage events in the NC-SP2-p6 region have a
critical impact on resistance and fitness, and may constitute rate-
limiting events for HIV virion maturation both in the absence and
in the presence of PIs. This conclusion was confirmed by western
blot experiments examining the extent of cleavage of Gag proteins
in a series of VIS13-derived recombinant and mutants viruses. We
first observed that increasing LPV concentration had a similar
effect regarding CA processing in all viruses carrying resistance
mutations in PR. This was different from the recent in vitro
selection experiments, where mutations in SP2 at position 436 and
437 increased overall Gag processing [13]. We found, however,
that adding or removing the NC-SP2 cleavage site mutation
A431V in different VIS13-derived clones did have an effect on the
amount of fully processed NC relative to its partially cleaved
precursor NC-SP2. This effect was seen both in the absence or in
the presence of inhibitor, consistent with the expectations from the
structural analysis of the A431V mutant peptide with wild-type
and mutant PR [23]. Importantly, the NC/NC-SP2 processing
efficiency fully correlated with the resistance phenotypes of the
respective viruses. This finding is in apparent contradiction with
the results of mutagenesis experiments reporting that mutant
virions lacking cleavage at the NC-SP2 site were close to being
fully infectious [21]. Several explanations may be proposed to
reconcile our findings with those of Coren et al. First, the assay
systems used to monitor infectivity are not fully comparable and
may differ in their sensitivity to small changes in viral infectivity.
Second, these authors have essentially evaluated the effect of
mutagenesis of NC-SP2 with wild-type HIV PR from a laboratory
molecular clone in absence of protease inhibitor. It can be
hypothesized that the rate-limiting nature of cleavage at this site
may be more important in the context of primary PR sequences, of
resistant PR enzymes, and/or in virions assembled and matured in
the presence of protease inhibitors. In this regard, it is noteworthy
Figure 6. Replicative capacity of viral clones carrying mutations or reversions in Gag cleavage sites. Each panel shows the RC (in %
relative to NL4-3 RC) of a set of clones whose construction was based on the same patient-derived HIV-1 sequences. The sets of clones and the color
codes are identical to those presented in Figure 4 and described in the legend of Figure 4. Single asterisks indicate that the RC difference between
the indicated clone and the corresponding BS clone is statistically significant. Double asterisks indicate that the RC difference between the indicated
clone and the corresponding XS clone is statistically significant.
doi:10.1371/journal.ppat.1000345.g006
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HIV-1 strains that have never been exposed to PIs, and that in
vitro, mature NC has been found to exert optimal chaperone
function when compared to other Gag cleavage products,
including NC-SP2 [26]. In our experiments, the dramatic effects
of mutation A431V on resistance, its context-dependent impact on
RC, and its strong influence on the ratio of NC to NC-SP2,
strongly argues in favor of a critical role of this cleavage event in
vivo, in viruses having escaped to pharmacological pressure by
protease inhibitors.
Materials and Methods
Cells
HeLa cells and P4 cells (HeLa-CD4 LTR-LacZ) were cultivated
in Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal calf serum and antibiotics. P4 cells were cultured in the
presence of geneticin (500 mg/ml). P4 cells were used as indicator
target cells for HIV-1 infection both in resistance and in viral
replicative capacityassays [3,8,27–29].Infection of P4cells by HIV-
1 virions was monitored in a single cycle of infection, based on the
expression of ß-galactosidase, which, in this cell line, is strictly
dependent upon induction by the HIV-1 Tat transactivator protein.
Construction of recombinant viruses with patient-
derived Gag, PR, and RT sequences
HIV-1 Gag-Pol plasma sequences from 6 patients with multiple
drug resistance were PCR-amplified and cloned into pNL4-3. The
patients were recruited from the ANRS 109 ‘‘Vista’’ study, a pilot
study aimed at evaluating the virological and immunological
consequences of a treatment simplification in patients with
multiple antiretroviral drug resistance and no options for
suppressive therapy [30]. All 6 patients had a history of failure
of multiple lines of combination antiretroviral therapy, which
included several protease inhibitors. The recombinant viruses
carried different segments of Gag, and/or PR-RT sequences from
plasma virus (up to RNAse-H junction) in an NL4-3 background
(Figure 3). The GenBank accession numbers for the sequences are
VIS09: bankit1176725 FJ649603; VIS13: bankit1176730
FJ649604; VIS15: bankit1176735 FJ649605; VIS16:
bankit1176737 FJ649606; VIS18: bankit1176743 FJ649607;
VIS20: bankit1176745 FJ649608. RNA was isolated using a
Qiagen extraction kit, and the whole-gag protease and reverse
transcriptase encoding regions were reverse transcribed and
amplified by nested PCR. Nested PCR primers were designed to
contain one enzyme restriction site each : BssHII+ (59 TGC TGA
AGC GCG CAC GGC AAG A) and SnaBI- (59 CCC ATC TAC
GTA GAA AGT TTC TGC). The PCR product was digested by
BssHII and SnaBI and used to replace the corresponding fragment
of pNL4-3, generating a full-length clone (BS clone) carrying the
complete gag-protease-RT sequences derived from each patient
(between base pairs 711 and 3870 of pNL4-3).
As shown on Figure 3, these 6 BS clones were then used as the
source of the gag-pol gene for the construction of three different
types of recombinant viruses : i) AS clones, which contained
patient-derived NC/p1/p6 protease and reverse transcriptase
sequences between the ApaI and SnaBI restriction sites; ii) XS
clones, which contained patient-derived PR and RT sequences
between the XbaI site and the SnaBI site in association with NL4-
3-derived Gag; iii) BX clones, carrying patient-derived Gag
between BssHII and XbaI, in association with NL4-3 PR and
RT sequences. Introduction of patient-derived sequences into
pNL4-3 using the indicated restriction enzymes was made possible
by PCR amplification of the corresponding segments of viral
genome with primers displaying unique restriction sites. Primers
ApaI+ (59GAA ATT GTA GGG CCC CTA GGA AAA AG) and
SnaBI- were used to introduce the restriction sites ApaI at the 59
and and SnaBI at the 39 end of the 1862 bp AS fragment. By the
same process, XbaI (59 GGA GCC TCT AGA CAA GGA ACT
GTA TCC T) and SnaBI restriction sites were added to the 59 and
39 ends of the PR-RT fragment and BssHII and XbaI restriction
sites were added to the 59 and 39 ends of the Gag fragment.
Six other recombinant viruses were constructed by site-directed
mutagenesis. First, to remove and replace the cleavage site
mutations (A431V, I437V) of the patient-derived Gag-PR-RT
fragmentwiththe wild type pNL4-3amino acid pattern andsecond,
to add these mutations in the recombinant viruses containing the
patient-derived PR-RT fragment. The oligonucleotides used for
these mutagenesis experiments are listed in Table S1.
Protease inhibitor susceptibility assay
HeLa cells cultivated in 25 cm
2 flasks were transfected with
5 mg of HIV plasmid DNA by the calcium phosphate precipitate
method. After 18 hours of incubation, transfected cells were
subcultured in triplicate in 96 well plates in the presence of serial
dilutions of 6 protease inhibitors. After 30 hours, viral superna-
tants containing 1–2 ng of p24 antigen were used to infect
subconfluent P4 cells in 96 well plates in the presence of DEAE-
dextran (15 mg/ml). Forty hours later the single cycle virus titer
was determined by quantification of the ß-galactosidase activity in
the P4 lysates, using a colorimetric assay based on the cleavage of
chlorophenol red-ß-D-galactopyranoside (CPRG). Optical densi-
ties in the reaction wells were read at 570 nm with a reference
filter set at 690 nm.
Replicative capacity assay
293T cells cultivated in 25 cm
2 flasks were transfected with 3 mg
of HIV plasmid DNA by the calcium phosphate precipitation
method. After 18 hours, the precipitate was removed by gentle
washing and fresh medium was added. After a further 24 hours of
culture, the supernatant was clarified by centrifugation at 5006g
for 15 min and quantified for HIV-1 p24 content by Elisa. P4
indicator cells were infected with two-fold dilutions of the
supernatant, representing a range of p24 concentrations from
0.78 ng/ml to 50 ng/ml, in the presence of DEAE-dextran
(15 mg/ml). Forty hours later, ß-galactosidase activity in P4 cells
was measured by CPRG assay as described above, optical density
values plotted as a function of the p24 content in the viral
inoculum, and the slope determined by linear regression.
Replication capacity was then calculated as the ratio between
the slope measured for the tested virus to that of reference virus
NL4-3 and expressed as a percentage.
Figure 7. Western-blot analysis of CA and NC products in purified virions produced by viral clones carrying mutations or reversions
in Gag cleavage sites. Virions produced by the indicated VIS13-derived clones were purified, lysed, and analyzed by Western blotting using a
primary antibody mixture of rabbit anti-CA and goat anti-NC antibodies and secondary antibodies yielding green fluorescence for NC and red
fluorescence for CA. Blots were scanned using the Licor Odyssey Infrared Imaging System and quantified with the Licor software. (A) Shows analysis
of CA-reactive products on a regular 12.5% polyacrylamide-SDS-gel, while (B) shows NC- and CA-reactive products on a tricine gel yielding better
resolution in the low molecular mass range. Quantification of the NC-reactive signals is presented in (C).
doi:10.1371/journal.ppat.1000345.g007
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293T cells were transfected using the calcium phosphate
method in 6-well plates using 2 mg DNA per well. Medium was
changed 6 h after transfection and cells and particles were
harvested 48 h after transfection. Particles were recovered from
clarified culture medium by centrifugation for 1 h at 44,000 rpm
through a 20% sucrose cushion in a TLA45 rotor. Cell and
particle lysates were separated either on 12.5% standard
polyacrylamide gels or on 14% acrylamide tricine gels for superior
resolution of smaller proteins as described [31]. Proteins were
transferred to Immobilon FL (Millipore) and reacted with a
mixture of polyclonal rabbit anti-CA (1:5,000) and goat anti-NC
(1:3,000; kind gift of Dr. J. Lifson, NCI) followed by a mixture of
donkey anti-rabbit IRdye700CW (Licor; 1:20,000) and donkey
anti goat IRdye800CW (Licor; 1:20,000). Blots were scanned
using the Licor Odyssey Infrared Imaging System and quantified
with the Licor software as specified by the manufacturer.
Statistical analyses
IC50 values and fold-changes in IC50 were compared using a
one-way ANOVA test. A p,0.05 was considered to be statistically
significant. When groups differed significantly, a Bonferroni
multiple comparison post-test was performed to make two by
two comparisons.
Supporting Information
Table S1 Primers used for site-directed mutagenesis
Found at: doi:10.1371/journal.ppat.1000345.s001 (0.03 MB
DOC)
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